MDLN
NEUTRAL
$47.22
Live
Medline Inc. · NASDAQ
Target $53.52
(+13.3%)
$34.89
52W Range
$50.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$38.33B
P/E
33.02
ROE
6.5%
Profit margin
4.1%
Debt/Equity
0.67
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MDLN exhibits strong fundamental health with a Piotroski F-Score of 7/9 and exceptional liquidity (Current Ratio 4.29), suggesting a stable operational baseline. However, the stock is currently trading at a premium to its Intrinsic Value ($42.18) and significantly above its Graham Number ($20.63). This valuation gap, combined with a starkly bearish technical trend and massive insider liquidation exceeding $3.5 billion, offsets the positive analyst consensus and revenue growth.
Key Strengths
Strong Piotroski F-Score (7/9) indicating high financial health
Excellent liquidity with a Current Ratio of 4.29 and Quick Ratio of 2.21
Solid top-line revenue growth of 14.80% YoY
Conservative leverage with a Debt/Equity ratio of 0.67
Strong analyst support with a 'Buy' recommendation and target price of $53.52
Key Risks
Extreme insider selling by beneficial owners (>10% holders) totaling $3.5B+
Trading at a premium to growth-based intrinsic value ($47.22 vs $42.18)
Very thin profit margins (4.08%) leaving little room for operational error
Bearish technical trend (10/100) suggesting negative short-term momentum
Significant discrepancy between analyst optimism and insider behavior
AI Fair Value Estimate
Based on comprehensive analysis
$42.18
-10.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
51
Moderate
40
65
60
92
0
AI Verdict
Fundamentally robust but internally distrusted
Key drivers: Piotroski F-Score, Insider Selling, Liquidity Ratios, Valuation Premium
Confidence
90%
Value
40/100
Ref P/E 33.02, Graham Number $20.63
Positives
- P/E is significantly lower than the healthcare sector average of 89.89
Watchpoints
- Price is 129% above Graham Number
- Price exceeds Intrinsic Value estimate
Future
65/100
Ref Growth rates and Analyst Targets
Positives
- Strong YoY revenue growth (14.8%)
- Positive analyst target price ($53.52)
Watchpoints
- Recent Q/Q earnings growth decline of 37%
Past
60/100
Ref Historical price changes
Positives
- Consistent 1Y price performance of +15.2%
Watchpoints
- Technical trend is currently heavily bearish
Health
92/100
Ref Piotroski F-Score and Liquidity Ratios
Positives
- Piotroski F-Score 7/9
- Very high Current Ratio (4.29)
- Low Debt/Equity (0.67)
Watchpoints
- Altman Z-Score data unavailable
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$47.22
Analyst Target
$53.52
Upside/Downside
+13.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MDLN and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MDLN
Medline Inc.
Primary
|
+15.2% | +15.2% | +15.2% | +15.2% | +13.9% | +7.6% |
|
A
Agilent Technologies, Inc.
Peer
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
ALNY
Alnylam Pharmaceuticals, Inc.
Peer
|
+114.5% | +67.5% | +29.6% | -32.7% | -2.8% | -2.3% |
|
INSM
Insmed Incorporated
Peer
|
+402.3% | +817.7% | +138.9% | -4.6% | +11.1% | -4.7% |
MDL
Medline Inc.
Primary
5Y
+15.2%
3Y
+15.2%
1Y
+15.2%
6M
+15.2%
1M
+13.9%
1W
+7.6%
A
Agilent Technologies, Inc.
Peer
5Y
+11.4%
3Y
-11.3%
1Y
-10.7%
6M
+12.8%
1M
-2.2%
1W
-3.3%
ALC
Alcon Inc.
Peer
5Y
+8.8%
3Y
+9.9%
1Y
-9.6%
6M
-12.6%
1M
+0.1%
1W
+1.6%
ALN
Alnylam Pharmaceuticals, Inc.
Peer
5Y
+114.5%
3Y
+67.5%
1Y
+29.6%
6M
-32.7%
1M
-2.8%
1W
-2.3%
INS
Insmed Incorporated
Peer
5Y
+402.3%
3Y
+817.7%
1Y
+138.9%
6M
-4.6%
1M
+11.1%
1W
-4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
33.02
Forward P/E
28.54
PEG Ratio
N/A
P/B Ratio
3.57
P/S Ratio
1.35
EV/Revenue
2.04
EV/EBITDA
18.16
Market Cap
$38.33B
Profitability
Profit margins and return metrics
Profit Margin
4.08%
Operating Margin
5.69%
Gross Margin
26.44%
ROE
6.53%
ROA
3.66%
Growth
Revenue and earnings growth rates
Revenue Growth
+14.8%
Earnings Growth
+1254.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-37.0%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.67
Moderate
Current Ratio
4.29
Strong
Quick Ratio
2.21
Excellent
Cash/Share
$2.43
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$7.8B
Gross Margin
24.6%
Op. Margin
5.5%
Net Margin
2.3%
Total Assets
$38.5B
Liabilities
$19.2B
Equity
$10.7B
Debt/Equity
1.79x
Operating CF
$0.2B
CapEx
$-0.1B
Free Cash Flow
$0.1B
FCF Yield
40%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-25
$0.38
+59.9% surprise
Healthcare Sector Comparison
Comparing MDLN against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
P/E Ratio
33.02
This Stock
vs
88.11
Sector Avg
-62.5%
(Discount)
Return on Equity (ROE)
6.53%
This Stock
vs
-86.0%
Sector Avg
-107.6%
(Below Avg)
Profit Margin
4.08%
This Stock
vs
-11.76%
Sector Avg
-134.7%
(Weaker)
Debt to Equity
0.67
This Stock
vs
3.51
Sector Avg
-80.8%
(Less Debt)
Revenue Growth
14.8%
This Stock
vs
90.15%
Sector Avg
-83.6%
(Slower)
Current Ratio
4.29
This Stock
vs
3.67
Sector Avg
+17.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MDLN
Medline Inc.
|
NEUTRAL | $38.33B | 33.02 | 6.5% | 4.1% | $47.22 | |
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | Compare |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | Compare |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $41.57B | 135.09 | 73.3% | 8.4% | $313.41 | Compare |
|
INSM
Insmed Incorporated
|
BEARISH | $33.42B | - | -249.3% | -210.5% | $154.81 | Compare |
MDLN
Medline Inc.
NEUTRAL
Mkt Cap
$38.3B
P/E
33.0
ROE
6.5%
Price
$47.22
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 26,105,840 | $1,070,339,440 |
| 2026-03-10 | HELLMAN & FRIEDMAN CAPITAL PARTNERS X PARALLEL, L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | 26,131,237 | $1,058,524,148 |
| 2026-03-05 | CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 9,297,883 | - |
| 2026-03-05 | HELLMAN & FRIEDMAN CAPITAL PARTNERS X PARALLEL, L.P | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 15,178,751 | - |
| 2026-03-05 | LAABS AMANDA H. | Officer | Stock Award | 25,788 | - |
| 2026-03-05 | ABRAMS WILLIAM J. | Officer | Stock Award | 17,854 | - |
| 2026-03-05 | MILLER STEPHEN L. | Chief Operating Officer | Stock Award | 25,788 | - |
| 2026-03-05 | GOLWAS DOUGLAS P. | Officer | Stock Award | 25,788 | - |
| 2026-03-05 | SHRYOCK CHRISTOPHER P. | Officer | Stock Award | 11,903 | - |
| 2026-03-05 | BOYLE JIM M. | Chief Executive Officer | Stock Award | 31,739 | - |
| 2026-03-05 | LIBERMAN ALEX M. | Officer | Stock Award | 11,903 | - |
| 2026-03-05 | DRAZIN MICHAEL B. | Chief Financial Officer | Stock Award | 25,788 | - |
| 2026-03-05 | BX MOZART ML-1 HOLDCO L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 9,487,267 | - |
| 2025-12-18 | CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 19,136,333 | $755,885,154 |
| 2025-12-18 | CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 6,815,617 | - |
CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
26,105,840 shares
·
$1,070,339,440
HELLMAN & FRIEDMAN CAPITAL PARTNERS X PARALLEL, L.P
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
26,131,237 shares
·
$1,058,524,148
CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
2026-03-05
9,297,883 shares
HELLMAN & FRIEDMAN CAPITAL PARTNERS X PARALLEL, L.P
Beneficial Owner of more than 10% of a Class of Security
2026-03-05
15,178,751 shares
LAABS AMANDA H.
Officer
2026-03-05
25,788 shares
ABRAMS WILLIAM J.
Officer
2026-03-05
17,854 shares
MILLER STEPHEN L.
Chief Operating Officer
2026-03-05
25,788 shares
GOLWAS DOUGLAS P.
Officer
2026-03-05
25,788 shares
SHRYOCK CHRISTOPHER P.
Officer
2026-03-05
11,903 shares
BOYLE JIM M.
Chief Executive Officer
2026-03-05
31,739 shares
LIBERMAN ALEX M.
Officer
2026-03-05
11,903 shares
DRAZIN MICHAEL B.
Chief Financial Officer
2026-03-05
25,788 shares
BX MOZART ML-1 HOLDCO L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-03-05
9,487,267 shares
CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
2025-12-18
19,136,333 shares
·
$755,885,154
CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
2025-12-18
6,815,617 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
27 analysts
JP Morgan
2026-03-10
Overweight
Overweight
Tigress Financial
2026-03-09
Buy
Buy
BTIG
2026-03-09
Buy
Buy
Morgan Stanley
2026-03-02
Overweight
Overweight
Wells Fargo
2026-02-27
Equal-Weight
Equal-Weight
Citigroup
2026-02-26
Buy
Buy
UBS
2026-02-26
Buy
Buy
BMO Capital
2026-02-26
Outperform
Outperform
RBC Capital
2026-02-26
Outperform
Outperform
Evercore ISI Group
2026-02-26
Outperform
Outperform
Past News Coverage
Recent headlines mentioning MDLN from our newsroom.
Newest → oldest
No matching news yet.